148 related articles for article (PubMed ID: 20146633)
1. PAK as a therapeutic target in gastric cancer.
Li X; Liu F; Li F
Expert Opin Ther Targets; 2010 Apr; 14(4):419-33. PubMed ID: 20146633
[TBL] [Abstract][Full Text] [Related]
2. Targeting group II PAKs in cancer and metastasis.
Eswaran J; Soundararajan M; Knapp S
Cancer Metastasis Rev; 2009 Jun; 28(1-2):209-17. PubMed ID: 19160016
[TBL] [Abstract][Full Text] [Related]
3. PAKs in human disease.
Chan PM; Manser E
Prog Mol Biol Transl Sci; 2012; 106():171-87. PubMed ID: 22340718
[TBL] [Abstract][Full Text] [Related]
4. Group II p21-activated kinases as therapeutic targets in gastrointestinal cancer.
Shao YG; Ning K; Li F
World J Gastroenterol; 2016 Jan; 22(3):1224-35. PubMed ID: 26811660
[TBL] [Abstract][Full Text] [Related]
5. p21-activated kinases and gastrointestinal cancer.
He H; Baldwin GS
Biochim Biophys Acta; 2013 Jan; 1833(1):33-9. PubMed ID: 23092728
[TBL] [Abstract][Full Text] [Related]
6. p21-Activated kinases as promising therapeutic targets in hematological malignancies.
Wu A; Jiang X
Leukemia; 2022 Feb; 36(2):315-326. PubMed ID: 34697424
[TBL] [Abstract][Full Text] [Related]
7. p21-Activated kinase inhibitors: a patent review.
Crawford JJ; Hoeflich KP; Rudolph J
Expert Opin Ther Pat; 2012 Mar; 22(3):293-310. PubMed ID: 22404134
[TBL] [Abstract][Full Text] [Related]
8. p21-activated kinase inhibitors.
Rudolph J; Crawford JJ; Hoeflich KP; Chernoff J
Enzymes; 2013; 34 Pt. B():157-80. PubMed ID: 25034104
[TBL] [Abstract][Full Text] [Related]
9. Inhibitors of p21-activated kinases (PAKs).
Rudolph J; Crawford JJ; Hoeflich KP; Wang W
J Med Chem; 2015 Jan; 58(1):111-29. PubMed ID: 25415869
[TBL] [Abstract][Full Text] [Related]
10. 2-amino-N-{4-[5-(2-phenanthrenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]-phenyl} acetamide (OSU-03012), a celecoxib derivative, directly targets p21-activated kinase.
Porchia LM; Guerra M; Wang YC; Zhang Y; Espinosa AV; Shinohara M; Kulp SK; Kirschner LS; Saji M; Chen CS; Ringel MD
Mol Pharmacol; 2007 Nov; 72(5):1124-31. PubMed ID: 17673571
[TBL] [Abstract][Full Text] [Related]
11. PAK signalling during the development and progression of cancer.
Radu M; Semenova G; Kosoff R; Chernoff J
Nat Rev Cancer; 2014 Jan; 14(1):13-25. PubMed ID: 24505617
[TBL] [Abstract][Full Text] [Related]
12. UnPAKing the class differences among p21-activated kinases.
Eswaran J; Soundararajan M; Kumar R; Knapp S
Trends Biochem Sci; 2008 Aug; 33(8):394-403. PubMed ID: 18639460
[TBL] [Abstract][Full Text] [Related]
13. A tale of two Paks.
Arias-Romero LE; Chernoff J
Biol Cell; 2008 Feb; 100(2):97-108. PubMed ID: 18199048
[TBL] [Abstract][Full Text] [Related]
14. The emerging importance of group II PAKs.
Wells CM; Jones GE
Biochem J; 2010 Jan; 425(3):465-73. PubMed ID: 20070256
[TBL] [Abstract][Full Text] [Related]
15. p21-Activated Kinases in Thyroid Cancer.
Bautista L; Knippler CM; Ringel MD
Endocrinology; 2020 Aug; 161(8):. PubMed ID: 32609833
[TBL] [Abstract][Full Text] [Related]
16. Emerging functions of p21-activated kinases in human cancer cells.
Kumar R; Vadlamudi RK
J Cell Physiol; 2002 Nov; 193(2):133-44. PubMed ID: 12384990
[TBL] [Abstract][Full Text] [Related]
17. p21-activated kinase 1: PAK'ed with potential.
Ong CC; Jubb AM; Zhou W; Haverty PM; Harris AL; Belvin M; Friedman LS; Koeppen H; Hoeflich KP
Oncotarget; 2011 Jun; 2(6):491-6. PubMed ID: 21653999
[TBL] [Abstract][Full Text] [Related]
18. Involvement of Rac/Cdc42/PAK pathway in cytoskeletal rearrangements.
Szczepanowska J
Acta Biochim Pol; 2009; 56(2):225-34. PubMed ID: 19513348
[TBL] [Abstract][Full Text] [Related]
19. Targeting AKT protein kinase in gastric cancer.
Almhanna K; Strosberg J; Malafa M
Anticancer Res; 2011 Dec; 31(12):4387-92. PubMed ID: 22199303
[TBL] [Abstract][Full Text] [Related]
20. PAK1 as a therapeutic target.
Kichina JV; Goc A; Al-Husein B; Somanath PR; Kandel ES
Expert Opin Ther Targets; 2010 Jul; 14(7):703-25. PubMed ID: 20507214
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
